European Union #6009 (v.2)

Base data

Notified in
Version validity
13/03/2021 - 26/03/2021
Old version v.2
Reporting member
European Union
In force from
End date
In force
General description
Export authorisation for COVID-19 vaccines
National legal basis
Commission Implementing Regulation (EU) 2021/442 of 12 March 2021 making the exportation of certain products subject to the production of an export authorisation;
Official Journal L 85, 12.03.2021

https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32021R0442&from=EN


Application period: from 13.03.2021 until 30.06.2021
Administrative mechanism
Administration: Competent authorities in EU Member States

Exemptions include
(see Article 1.5 of the regulation):

- exports in the context of humanitarian aid;

- exports to low and middle income countries in the COVAX Advance Market Commitment (AMC) list (https://www.gavi.org/news/media-room/92-low-middle-income-economies-eligible-access-covid-19-vaccines-gavi-covax-amc );

exports of goods purchased and/or delivered through COVAX, UNICEF and PAHO with destination to any other COVAX participating country;


- Albania, Algeria, Andorra, Armenia, Azerbaijan, Belarus, Bosnia and Herzegovina, Egypt, Faeroe Islands, Georgia, Holy See, Iceland, Israel, Jordan, Kosovo(see Footnote 1) , Lebanon, Libya, Liechtenstein, Moldova, Montenegro, Morocco, Norway, North Macedonia, Palestine(see Footnote 2) , San Marino, Serbia, Switzerland, Syria, Tunisia, Ukraine;

- EU overseas countries and territories

Footnote 1:This designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.
Footnote 2: This designation shall not be construed as recognition of a State of Palestine and is without prejudice to the individual positions of the EU Member States on this issue.
Responsible entities
Competent authorities in EU Member States
HS version
HS 2017
Referenced WTO document symbol

Meta data

WTO justifications

No specific provision provided

No specific provision provided

Reported as: Protection of human life or health, inter alia
Non-WTO commitments
Affected partners
Non-affected partners

Measures

Reported restrictions
NAL-X
Symbol
NAL-X

Tariff lines

300220
ex 3002 20
Vaccines against SARS-related coronaviruses (SARS-CoV species), irrespective of their packaging, and...